HALO Q1 Deep Dive: Royalty Expansion and Pipeline Progress Shape 2026 Outlook
Halozyme Therapeutics (NASDAQ:HALO) reported a sharp increase in first-quarter 2026 revenue and earnings, driven by continued growth in royalties from its ENHANZE drug-delivery platform, and announced...
Halozyme Therapeutics: Q1 Earnings Snapshot
Halozyme Therapeutics’s (NASDAQ:HALO) Q1 CY2026 Sales Top Estimates
Announcing New $1 billion Share Repurchase Program Projecting to Buy Back at Least $400 million in 2026
Barchart Research What to Expect from HALO Earnings HALO Generated May 8, 2026 Current Price $64.12 EPS Estimate $$1.46 Consensus Rating Moderate Buy Average Move 6.47% Halozyme: A Decade of Platform Revenue...
Halozyme Therapeutics Earnings: What To Look For From HALO
Barchart Research What to Expect from HALO Earnings HALO Generated May 8, 2026 Current Price $64.12 EPS Estimate $$1.46 Consensus Rating Moderate Buy Average Move 6.47% Halozyme: A Decade of Platform Revenue...
Barchart Research What to Expect from HALO Earnings HALO Generated May 8, 2026 Current Price $64.12 EPS Estimate $$1.46 Consensus Rating Moderate Buy Average Move 6.47% Halozyme: A Decade of Platform Revenue...
Marks first ENHANZE ® agreement to include ADC targets